Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

tofacitinib topical cream

A topical cream formulation containing the Janus kinase (JAK) inhibitor tofacitinib, with potential immunomodulatory and anti-inflammatory activities. Upon topical administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha (IFN-a) and -beta (IFN-b), and may prevent both an inflammatory response and the inflammation-induced damage caused by certain diseases. JAK are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:tofacitinib cream
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search